biOasis Technologies Inc. is a ground-breaking biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier and into the brain tissue. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in the treatment of over a thousand common and rare diseases of the central nervous system.
biOasis is seeking to address these unmet medical needs with its proprietary Transcend Platform. Designed to transport therapeutics of varying types and sizes across the blood-brain barrier, the Transcend Platform is based on Receptor Mediated Transcytosis, nature’s own method of carrying compounds into the brain.
Located in Vancouver, Canada, biOasis is a publicly-traded company on the OTCQB under the symbol BIOAF and on the TSX Venture Exchange under BTI.
biOasis’ business strategy is to develop and commercialize its proprietary Transcend drug-delivery Platform through the advancement of high value internal therapeutic programs, while executing broad licensing models with reputable pharmaceutical partners for the advancement of their therapeutics to clinical trials and commercialization.